Human Papillomavirus (HPV) Infection Vaccines Market – Global Industry Insights, Trends, Outlook and Opportunity Analysis 2018-2025

Google+ Pinterest LinkedIn Tumblr +

Human papillomavirus infection is most common sexually transmitted infection caused by HPV-related cancers such as cervical and genital cancer. Human papillomavirus infection vaccines are used to prevent genital wart, anal cancer, cervical cancer, and vaginal cancer. Three commercially available HPV prevention vaccine such as Gardasil and Gardasil 9 by Merck & Co., Inc. and Cervarix by GlaxoSmithKline plc, are proven to be highly effective in preventing of HPV infection and genital precancerous lesions. The adoption of preventive vaccines shifted the paradigm of diseases, and are expected to have a major impact in reducing the burden of cervical cancer, HPV-associated malignancies, and benign tumors. The key factors driving growth of the human papillomavirus infection vaccine market include large number of pipeline products, increasing research for therapeutic vaccine, governmental initiative for immunization program, and high prevalence of HPV-related infectious disease.

To understand Research Methodology, please click: https://www.coherentmarketinsights.com/insight/request-sample/1588

Human Papillomavirus (HPV) Infection Vaccines Market Driver

Large number of clinical trials conducted by pharmaceutical and biopharmaceutical companies are expected to fuel growth of the HPV infection vaccine market during the forecast period. For instance, Merck & Co., Inc., is conducting Phase III clinical trial for it quadrivalent human papillomavirus recombinant vaccine for type 6, 11, 16, and 18. Moreover, Shanghai Bovax Biotechnology Co., Ltd., is engaged in evaluating safety and primary immunogenicity of the quadrivalent human papillomavirus vaccine in female population of China. Currently studies are in phase I clinical trial. Furthermore, Serum Institute of India Pvt. Ltd., is developing tetravalent HPV vaccine, which is expected to provide protection of around 90% against HPV infections, which are prevalent in the emerging economies such as India and China.

Moreover, increasing research on therapeutic vaccine for treatment of HPV infection to address unmet medical need is expected to boost growth of the human papilloma virus (HPV) infection vaccines market. For instance, Profectus BioSciences, Inc., is engage in developing GeneVax prime/VesiculoVax, a therapeutic vaccine for HPV infection. The vaccine is expected to be effective against seven HPV types. Moreover, Inovio Pharmaceuticals, Inc., is investigating VGX-3100 as candidate for immunotherapy to demonstrate efficacy against cervical HSIL associated with HPV-16 and HPV-18. VGX-3100 is divalent DNA plasmid-based therapeutic vaccine, which completed phase 2b clinical trial in 2015 and initiated phase 3 in June 2017.

Governmental and non-governmental organization plays important role in increasing awareness through immunization program, in turn driving growth of the human papillomavirus infection vaccine market. For instance, in 2012, the Global Alliance for Vaccines and Immunization (GAVI) support for HPV vaccine introduction targeted to reach 30 million girls in emerging economies by 2020. In 2016, Joint UN Global Programme was set up for prevention of cervical cancer, which includes vaccination in high disease burden countries.

Furthermore, global HPV-related disease burden is expected to drive growth of the human papillomavirus (HPV) infection vaccines market. According to National Cancer Institute, 2015, HPV type 16 and type 18, causes around 70% of cervical cancer and is responsible for almost all cervical cancer. According to American Society of Clinical Oncology (ASCO), in 2017, an estimated 12,820 women in the U.S. are expected to be diagnosed with cervical cancer along with 4,210 deaths every year. According to World Health Organization (WHO), 2014, HPV type 6 and type 11 are responsible for 90% of the anogenital warts.

Human Papillomavirus (HPV) Infection Vaccines Market Restrains

The human papillomavirus infection vaccine market is expected to constrain by limited number of Food and Drug Administrations (FDA) approved commercial vaccines. High cost of vaccine development is also expected to hinder the human papillomavirus (HPV) infection vaccines market growth over the forecast period. Moreover, variable immunization coverage is estimated to impact the regional size. For instance, economies such as U.K and Mexico has 80% vaccination coverage whereas full-dosage coverage remains below 50% in France and in the U.S.

Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/1588

Human Papillomavirus (HPV) Infection Vaccines Market Regional Analysis

Regional segmentation of human papillomavirus (HPV) infection vaccine market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America comprises major share of the human papillomavirus infection treatment vaccine market, owing to high prevalence of cervical cancer, local market players and increasing governmental initiatives, followed by Europe. For instance, according to WHO 2016, currently 86% of America and 62% of European region girls have access to free HPV vaccination. Moreover, incidence of cervical cancer in Europe was 58,348 individuals per million in 2012. However, Asia Pacific is expected to witness significant growth during forecast period, due to awareness among the population for immunization.

Human Papillomavirus (HPV) Infection Vaccines Market Key Players

Major players operating in the HPV infection vaccine market include Merck & Co., Inc. and GlaxoSmithKline plc. The companies having the candidate for HPV vaccines are Shanghai Bovax Biotechnology Co., Ltd., Profectus BioSciences, Inc., 2A Pharma AB and ISA Pharmaceuticals.

Share.

About Author

Is an excellent researcher with expertise in the healthcare domain. His detailed research on topics related to recent breakthroughs in the genetic engineering, pharmacy, and healthcare fields coupled with his ability to concise his in-depth study in the best way possible, is of great advantage to this new portal. Contact Author

Comments are closed.